NEW ATTEMPT IN TUBERCULOSIS TREATMENT: AUTOLOGOUS CYTOKINE-INDUCED KILLER AFTER CHEMOTHERAPY TREATMENT FAILURE IN A CASE OF MULTI-DRUG RESISTANT TUBERCULOSIS (MTB)

Jun-Chi Xu1,2, Xin-Nian Chen2,3, Zhi-Jian Ye2,3, Mei-Ying Wu2,3, Cui-Lin Shi2,3, Pei-Jun Tang2,3, Hui Chen1,2, Xiao-Yan Zhu2,3, Hua-Feng Song2,3, Xu Ping2,3
1 Inspection Center. The Fifth People’s Hospital of Suzhou, Suzhou, China; 2 Key Laboratory of TB Prevention and Cure of Suzhou, Suzhou, China; 3 Department of Respiratory Medicine, The Fifth People’s Hospital of Suzhou, Suzhou, China

Abstract. A 32-year-old woman was diagnosed as pulmonary tuberculosis 15 years ago and recurred several times due to long-term nonstandard treatment. Drug sensitivity test indicated that multidrug-resistant tuberculosis had emerged and we determined relevant therapeutic schedule according to this result. However, it didn’t show any amelioration of the disease after 3-month chemotherapy. We formulated 3-course CIK immunotherapy based on patient’s condition. After 3 courses of immunotherapy, we found obvious amelioration of the patient’s condition. And there was no recurrence during the follow-up in the past 3 years. Therefore, we considered that the CIK immunotherapy is an effective method for tuberculosis treatment and recurrence prevention. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 97-99)

Key words: cell therapy, multi-drug resistant tuberculosis, CIK

INTRODUCTION

Since the 1980s, there has been a trend of resurgence of tuberculosis (TB) epidemic in both developed and developing countries. One of the main reasons for the resurgence of TB epidemic is the epidemic of multi-drug resistant TB (MDR-TB). In the global tuberculosis report 2015 of WHO had report that in 2014, there were an estimated 480 000 new cases of MDR-TB worldwide, and approximately 190 000 deaths from MDR-TB. The report also report that only 50% of patients on MDR-TB treatment were successfully treated and the treatment methods of MDR-TB were still insufficient (1).

Since autologous CIK immunotherapy can stimulate the body’s immune function and have a special role of supportive treatment for the body (2–4), we use CIK immunotherapy in the treatment of tuberculosis. Here, we report one case of chemotherapy treatment failure patient with MDR-TB that was improved after only CIK immunotherapy.
March 2012 because of aggravation for half a year. Patient history: She was diagnosed as pulmonary tuberculosis 15 years ago and underwent a 2-month anti-tuberculosis therapy, but she stopped unauthorizedly due to the side effect and didn’t receive any standard treatment. She was diagnosed as secondary pulmonary tuberculosis four years ago. She was given anti-tuberculosis treatment and still suffered from repeating cough and expectoration after the anti-tuberculosis course. The patient’s cough and expectoration aggravated 3 years ago, coughed purulent sputum and was admitted to our hospital in March 2012. Examination on admission: T: 38°; P: 106 beats/min; R: 27 beats/min; BP: 110/65 mmHg; severely marasmus; weight: 40 kg; chest CT: uneven density in bilateral lung with partial densification and calcification, cavity in upper right lung (Figure 1A,B). Sputum smear and culture showed a tubercle-bacillus-positive result and drug sensitivity test indicated widespread multidrug-resistant tubercle bacillus (Table 1A,B,C); flow cytometry analysis found a higher percentage of B cells and Treg cells (Figure 1E). Therefore, the patient was diagnosed as widely multidrug-resistant pulmonary tuberculosis and given the appropriate chemotherapy based on susceptibility testing.

After 3 months treatment, there was no evident amelioration and the inspection results showed exacerbation of the patient’s condition; persistent body weight loss and severe side effects such as violent vomiting occurred while using megadose of antibiotics; positive sputum smear and culture (Table 1A); flow cytometry showed a further decreasing percentage of CD4+ and CD8+ lymphocyte subsets as well as a further increasing percentage of B cells and Treg cells (Figure 1E). Because of the seriously illness and the failure of chemotherapy, we implemented the CIK cell with patient’s informed consent and approval. The CIK cells were given every other day, with a total of three times for six days and these six days were a course. The patient’s condition ameliorated obviously after a 3-course treatment of 90 days. And after the first course the sputum culture and sputum smear were both negative (Table 1A); We implemented a chest CT inspection for the patient after the third course of CIK immunotherapy and found pulmonary cavity was shrinking, the patch and nodule in some aspects were absorbed (Figure 1C,D). At the same time, through the follow-up we found that CD4+ and CD8+ lymphocyte subsets were increased and the B cell and Treg lymphocyte subsets were decreased after each immunotherapy (Figure 1E). There was no recurrence during the follow-up in the past 3 years.

**Discussion**

First discovered by of American Standford University in 1991 (5), CIK cell therapy is an immune
Cell therapy in tuberculosis

therapy that is most widely used clinically. It mainly involves the acquisition of a group of CD3+CD56+ double positive T cells through cytokines and in vitro culture, and kills tumor cells or pathogens by using the non-specificity of this group of cells (6). Through the summaries of its treatments of tumors, we discovered that CIK cells could secrete a large amount of cytokines during the treatment process, elevate patients’ ratios of CD4+/CD8+ and Th1/Th2 while reducing the proportion of Treg, and greatly stimulating the specific immune response of Th1 cells. This just inhibits the immune evasion mechanism of tuberculosis, thus enabling the body to regain the capacity of killing the tuberculosis. In our earlier research, we had found the CIK immunotherapy was safe, and combined with chemotherapy can speed up the improvement of the disease (7).

In this case, the patient accepted an agreement involving close follow-ups so as to facilitate the observations on the possible progression of her disease in the CIK immunotherapy. Fortunately, her condition was improved and through the close follow-ups we found that there was no recurrence until now. The success treatment of her disease convinced us the CIK immunotherapy is an effective method for tuberculosis treatment and recurrence prevention.

Acknowledgements

This work was funded by the science and technology plan of Suzhou, China (LCZX201414).

We thank the patient, clinicians, and support staff who participated in this study.

Human and animal rights:

This study was performed with the approval of the local ethical committee.

References

1. World Health Organization. Global tuberculosis report 2015: 54.
2. Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. W J G 2004; 10: 1146-51.
3. Yu J, Ren X, Cao S, et al. Th1 polarization and apoptosis-inducing activity of CD4+ T-cells in cytokine-induced killers might favor the antitumor cytotoxicity of cytokine-induced killers in vivo. Cancer biotherapy & radiopharmaceuticals 2006; 21: 276-84.
4. Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal immunol 2011; 4: 288-93.
5. Schmidt-Wolf IGH, Negrin R S, Kiem H P, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J EXP MED 1991; 174: 139-49.
6. Leemhuis T, Wells S, Scheffold C, et al. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation 2005; 11: 181-87.
7. Xu P, Xu JC, Chen XN, et al. Autologous cytokine-induced killer (CIK) immunotherapy in a case of disseminated tuberculosis. Sarcoidosis vasculitis and diffuse lung diseases 2015; 32: 83-6.

Table 1.

| STable 1A. Bacteriological examination | Admission examination | Before immunotherapy | First course of treatment | Second course of treatment | Third course of treatment |
|---------------------------------------|-----------------------|----------------------|--------------------------|--------------------------|--------------------------|
| Smear                                 | Positive(3+)          | Positive(3+)         | Not detected             | Not detected             | Not detected             |
| Culture                               | Positive              | Positive             | Negative                 | Negative                 | Negative                 |

| STable 1B. Bacterial identification | Human-type tuberculosis classification |
|------------------------------------|--------------------------------------|
| Mycobacterium tuberculosis          | Mycobacterium                        |

| STable 1C. Bacteriological susceptibility testing |
|-----------------------------------------------|
| Name of antibiotics   | Results   | Name of antibiotics   | Results   |
|-----------------------|-----------|-----------------------|-----------|
| Streptomycin          | Resistance| Levofoxacin           | Resistance|
| Isoniazid             | Resistance| Aminosalicylate       | Sensitive |
| Rifampicin            | Resistance| Protonamide           | Resistance|
| Ethambutol            | Resistance| Amikacin              | Sensitive |